Cargando…

Biomarkers of Fibroproliferative Healing in Fibrosing Idiopathic Interstitial Pneumonias

AIMS: The main feature of fibrosing idiopathic interstitial pneumonias (fIIPs) is the fibroproliferative potential of underlying pathogenetic process. We hypothesize that the concentration of potential markers of fibroproliferative healing, PAR-2, TGF-β1, TNF-α and IL-4Rα in bronchoalveolar lavage f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vasakova, Martina, Sterclova, Martina, Stranska, Eliska, Mandakova, Petra, Skibova, Jelena, Matej, Radoslav
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Open 2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551240/ https://www.ncbi.nlm.nih.gov/pubmed/23346263 http://dx.doi.org/10.2174/1874306401206010160

Ejemplares similares

Role of interleukin 4 and its receptor in clinical presentation of chronic extrinsic allergic alveolitis: a pilot study
por: Sterclova, Martina, et al.
Publicado: (2013)

Interstitial Score and Concentrations of IL-4Rα, PAR-2, and MMP-7 in Bronchoalveolar Lavage Fluid Could Be Useful Markers for Distinguishing Idiopathic Interstitial Pneumonias
por: Bruzova, Magdalena, et al.
Publicado: (2021)

Effect of genotype on the disease course in idiopathic pulmonary fibrosis despite antifibrotic treatment
por: Sterclova, Martina, et al.
Publicado: (2021)

Bronchoalveolar lavage cell profiles and proteins concentrations can be used to phenotype extrinsic allergic alveolitis patients
por: Sterclova, Martina, et al.
Publicado: (2019)

The natural history of progressive fibrosing interstitial lung diseases
por: Kolb, Martin, et al.
Publicado: (2019)

PAR-2, IL-4R, TGF-β and TNF-α in bronchoalveolar lavage distinguishes extrinsic allergic alveolitis from sarcoidosis
por: MATĚJ, RADOSLAV, et al.
Publicado: (2014)

Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias
por: Hoeper, Marius M., et al.
Publicado: (2015)

Clinical profile of unclassifiable interstitial lung disease: Comparison with chronic fibrosing idiopathic interstitial pneumonias
por: Traila, Daniel, et al.
Publicado: (2017)

Scoring of the radiological picture of idiopathic interstitial pneumonia: a study to verify the reliability of the method
por: Kocova, Eva, et al.
Publicado: (2015)

Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: the EMPIRE registry study
por: Jovanovic, Dragana M., et al.
Publicado: (2022)

Diagnostic and prognostic biomarkers for progressive fibrosing interstitial lung disease
por: Watase, Mayuko, et al.
Publicado: (2023)

Beyond idiopathic pulmonary fibrosis: the world of progressive-fibrosing interstitial lung disease
por: Harari, Sergio
Publicado: (2018)

Idiopathic fibrosing mediastinitis
por: Manyeruke, F D, et al.
Publicado: (2021)

Impact of lymphocyte differential count > 15% in BALF on the mortality of patients with acute exacerbation of chronic fibrosing idiopathic interstitial pneumonia
por: Takei, Reoto, et al.
Publicado: (2017)

Association of serum monomeric periostin level with outcomes of acute exacerbation of idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia
por: Shimizu, Hiroshige, et al.
Publicado: (2021)

Nintedanib in children and adolescents with fibrosing interstitial lung diseases
por: Deterding, Robin, et al.
Publicado: (2023)

Renalase Challenges the Oxidative Stress and Fibroproliferative Response in COVID-19
por: Stojanovic, Dijana, et al.
Publicado: (2022)

Progression of fibrosing interstitial lung disease
por: Wong, Alyson W., et al.
Publicado: (2020)

Management of Fibrosing Interstitial Lung Diseases
por: Maher, Toby M., et al.
Publicado: (2019)

The utility of the Japanese Association for Acute Medicine DIC scoring system for predicting survival in acute exacerbation of fibrosing idiopathic interstitial pneumonia
por: Yamazaki, Ryo, et al.
Publicado: (2019)

CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies
por: Zanatta, Elisabetta, et al.
Publicado: (2023)

Glutathione peroxidase 3 localizes to the epithelial lining fluid and the extracellular matrix in interstitial lung disease
por: Schamberger, Andrea C., et al.
Publicado: (2016)

Chimeric galectin-3 and collagens: Biomarkers and potential therapeutic targets in fibroproliferative diseases
por: Nangia-Makker, Pratima, et al.
Publicado: (2022)

The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype
por: Olson, Amy L., et al.
Publicado: (2018)

The Burden of Progressive-Fibrosing Interstitial Lung Diseases
por: Cottin, Vincent, et al.
Publicado: (2022)

Management of patients with fibrosing interstitial lung diseases
por: Morrow, Lee E, et al.
Publicado: (2021)

Fibrosing interstitial lung diseases: knowns and unknowns
por: Cottin, Vincent, et al.
Publicado: (2019)

Idiopathic Interstitial Pneumonias
por: Lee, Paul J., et al.
Publicado: (2012)

Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE
por: Kolonics-Farkas, Abigél M., et al.
Publicado: (2020)

Combination of computed tomography imaging pattern and severity of respiratory failure as factors associated with prognosis for acute exacerbation of idiopathic chronic fibrosing interstitial pneumonia
por: Enokida, Keito, et al.
Publicado: (2023)

A case of idiopathic fibrosing pancreatitis.
por: Choi, H. J., et al.
Publicado: (1990)

Evaluating the fibroproliferative response to ventilator-induced lung injury
por: Curley, G, et al.
Publicado: (2010)

A cohort study of mortality predictors in patients with acute exacerbation of chronic fibrosing interstitial pneumonia
por: Usui, Yutaka, et al.
Publicado: (2013)

Extracellular Heat Shock Proteins as Therapeutic Targets and Biomarkers in Fibrosing Interstitial Lung Diseases
por: Tanguy, Julie, et al.
Publicado: (2021)

Biomarkers in Progressive Fibrosing Interstitial Lung Disease: Optimizing Diagnosis, Prognosis, and Treatment Response
por: Bowman, Willis S., et al.
Publicado: (2021)

Association of serum high-mobility group box protein 1 level with outcomes of acute exacerbation of idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia
por: Shimizu, Hiroshige, et al.
Publicado: (2018)

The natural history of progressive fibrosing interstitial lung diseases
por: Brown, Kevin K., et al.
Publicado: (2020)

Management and support of patients with fibrosing interstitial lung diseases
por: Barbera, Tyonn, et al.
Publicado: (2021)

Predictors of Mortality in Progressive Fibrosing Interstitial Lung Diseases
por: Chen, Xianqiu, et al.
Publicado: (2021)

The Role of Radiology in Progressive Fibrosing Interstitial Lung Disease
por: Abu Qubo, Ahmad, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ept664ge85e7uoevvp5rht92n2